Skip to main content

Table 3 Predictors of new-onset AF for diabetic patients taking hypoglycemic agents after propensity score weighting

From: Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

 

Hazard ratio (95% CI); P value

Univariate

Multivariate

DPP4i versus other hypoglycemic agents

0.65 (0.56–0.76); < 0.0001

0.69 (0.59–0.81); P < 0.0001

Age (years)

 < 65

1.00 (reference)

1.00 (reference)

 ≥ 65

5.76 (4.97–6.68); < 0.0001

4.75 (4.07–5.55); P < 0.0001

Female gender

0.87 (0.75–1.01); 0.0714

 

Chronic lung disease

2.28 (1.46–3.56); 0.0003

 

Chronic kidney disease

1.74 (1.37–2.21); < 0.0001

 

Hypertension

2.64 (2.22–3.13); < 0.0001

1.74 (1.45–2.06); P < 0.0001

Ischemic heart disease

3.84 (2.88–5.13); < 0.0001

1.98 (1.48–2.66); P < 0.0001

  1. ACEI angiotensin-converting-enzyme inhibitor, AF atrial fibrillation, ARB angiotensin II receptor antagonists, DM diabetes mellitus, DPP4i dipeptidyl peptidase-4 inhibitor, GLP-1 glucagon-like peptide-1, PAOD peripheral arterial obstructive disease, TZD thiazolidinedione